1,5 In this prespecified secondary analysis of the SELECT trial, semaglutide 2.4 mg reduced total events (first and subsequent) by 22% (MR 0.78; 95% CI 0.70–0.86; P<0.001), 1 reduced non-fatal ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Uptake of semaglutide remains low due to cost, supply issues, and payer approval challenges, despite its benefits. The SELECT trial demonstrated semaglutide's efficacy in reducing cardiovascular ...

This study was a prespecified secondary analysis of the SELECT trial, which was designed to determine the effect of semaglutide on total CV events in patients without diabetes aged ≥45 years ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, ...

SOUL was a double-blind, event-driven, superiority trial including 9,650 ... for GLP-1s, or for semaglutide specifically? The answer is no. The SUSTAIN and SELECT studies drove a lot of my ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...